Small Molecules: Choosing a Strategic, Scalable, and De-Risked Development Path
Early CMC decisions determine success. Learn how structured planning and enabling technologies accelerate small-molecule programs to the clinic.
Early-stage development of small molecule drug candidates remains a high-risk endeavor, particularly for small and mid-sized pharmaceutical companies operating under tight timelines, limited API availability, and constrained budgets. In this context, Chemistry, Manufacturing and Controls (CMC) strategy becomes a decisive success factor rather than a downstream technical formality.
In its e-book Small Molecules: Choosing the Right Development Path, experienced CDMO Aenova outlines a structured roadmap for early CMC decision-making that integrates scientific rigor, risk mitigation, and scalability from day one. The guide emphasizes the importance of early developability profiling – including physicochemical characterization, solid-state analysis, stability assessment, and API classification – as the foundation for rational formulation and process design. By identifying solubility, permeability, and polymorphism risks upfront, development teams can avoid costly late-stage reformulations and clinical delays.
A central element of the proposed approach is a stage-gate decision framework that aligns formulation strategy with API properties and business objectives. For poorly soluble or highly lipophilic compounds, the e-book discusses the targeted use of bioavailability-enhancing platforms such as hot-melt extrusion, spray drying, and lipid-based systems, each selected based on scientific rationale rather than platform bias.
Equally critical is the early integration of process development and GMP readiness. The e-book highlights how scalable technology platforms, API-sparing screening methods, and phase-appropriate analytical validation can ensure seamless transition from preclinical development to clinical trial material manufacturing. By embedding regulatory considerations and quality systems early, small companies can build robust CMC packages capable of withstanding investor and agency scrutiny.
Finally, the paper addresses proactive risk mitigation and the strategic value of integrated CDMO partnerships. An end-to-end model that combines formulation development, analytical services, scale-up, GMP manufacturing, packaging, and regulatory support under one roof reduces tech-transfer risks, streamlines communication, and increases the probability of delivering Phase I/II trials on schedule and with consistent product quality.
For pharmaceutical innovators seeking to de-risk their small molecule pipelines while preserving speed and capital efficiency, this e-book provides a science-driven and operationally pragmatic blueprint.
The complete e-book can be downloaded from
Aenova’s website
most read
VCI Welcomes US-EU Customs Deal
The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.
CHEManager International Media Kit 2026
Compelling solutions through strategic partnerships
Dow to Shut Down Three Upstream European Assets
Building on the April 2025 announcement, Dow will take actions across its three operating segments to support European profitability, resulting in the closure of sites in Germany and the UK.
Novo Nordisk to Cut 9,000 Jobs Globally in Major Restructuring
Novo Nordisk announced a global workforce reduction of approximately 9,000 positions to streamline operations and reinvest DKK 8 billion (€1 billion) in growth opportunities for diabetes and obesity treatments.